Efficacy and safety of 0.4 percent sodium hyaluronate for endoscopic submucosal dissection of gastric neoplasms

AIM:To evaluate the efficacy and safety of sodium hyaluronate solution(SH) in endoscopic submucosal dissection(ESD) of gastric neoplasms.METHODS:A prospective multicenter randomized,double blind,controlled trial was designed and utilized in this study.A total of 76 patients with 5-20 mm sized gastric neoplasms were enrolled at three academic hospitals in South Korea from June 2011 to October 2011.Patients were randomly assigned to the 0.4% sodium hyaluronate or control groups.All lesions underwent endoscopic ESD.ESD was performed with 0.4%SH and normal saline(NS) solution for submucosal injection.Efficacy was assessed using en bloc resection and the number of additional injections.Secondary evaluation variables were the volume of injection material,steepness of mucosal elevation,bleeding rate,procedural time and operator satisfaction.Finally,the safety was assessed by analyzing adverse events during the study.RESULTS:The usefulness rate in the 0.4%SH group and the controlled group had statistically significant difference under intention to treat(ITT) analysis(90.91% vs 61.11% P = 0.0041).Under per protocol(PP),the usefulness rate is statistically significant different(93.10% vs 61.76%,P = 0.0036).The difference in volume of the solution injected between 0.4%SH group and the controlled group and NS group was also statistically significant under intention to treat and per protocol analysis(ITT:0.03 ± 0.02 mL vs 0.06 ± 0.03 mL,P = 0.0003,PP:0.03 ± 0.02 mL vs 0.06 ± 0.03 mL,P = 0.0004).Satisfaction above the grade good was significantly higher in the SH group under intention to treat and per protocol analysis(ITT:90.91% vs 61.11%,P = 0.0041,PP = 93.11% vs 61.77%,P = 0.0022).Adverse events above grade 3 were not noticed in either group.All adverse events were treated and were judged as not associated with the submucosal injection solutions.CONCLUSION:0.4%SH solution is a safe and effective agent that doesn’t cause any significant adverse events and is useful for submucosal injection during ESD.     

Endoscopic advances in the management of gastric cancer and premalignant gastric conditions

Gastric cancer is the fifth most common cancer and in 2018, it was the third most common cause of cancer-related deaths worldwide. Endoscopic advances continue to be made for the diagnosis and management of both early gastric cancer and premalignant gastric conditions. In this review, we discuss the epidemiology and risk factors of gastric cancer and emphasize the differences in early vs late-stage gastric cancer outcomes. We then discuss endoscopic advances in the diagnosis of early gastric cancer and premalignant gastric lesions. This includes the implementation of different imaging modalities such as narrow-band imaging, chromoendoscopy, confocal laser endomicroscopy, and other experimental techniques. We also discuss the use of endoscopic ultrasound in the diagnosis and staging of early gastric cancer. We then discuss the endoscopic advances made in the treatment of these conditions, including endoscopic mucosal resection, endoscopic submucosal dissection, and hybrid techniques such as laparoscopic endoscopic cooperative surgery. Finally, we comment on the current suggested recommendations for surveillance of both gastric cancer and its premalignant conditions.     

Secondary endoscopic submucosal dissection for locally recurrent or incompletely resected gastric neoplasms

AIM To investigate the feasibility and safety of secondary endoscopic submucosal dissection(ESD) for residual or locally recurrent gastric tumors. METHODS Between 2010 and 2017, 1623 consecutive patients underwent ESD for gastric neoplasms at a single tertiary referral center. Among these, 28 patients underwent secondary ESD for a residual or locally recurrent tumor. Our analysis compared clinicopathologic factors between primary ESD and secondary ESD groups. RESULTS The en bloc resection and curative rate of resection of secondary ESD were 92.9% and 89.3%, respectively. The average procedure time of secondary ESD was significantly longer than primary ESD(78.2 min vs 55.1 min, P = 0.004), and the adverse events rate was not significantly different but trended slightly higher in the secondary ESD group compared to the primary ESD group(10.7% vs 3.8%, P = 0.095). Patients who received secondary ESD had favorable outcomes without severe adverse events. During a mean follow-up period, no local recurrence occurred in patients who received secondary ESD. CONCLUSION Secondary ESD of residual or locally recurrent gastric tumors appears to be a feasible and curative treatment though it requires greater technical efficiency and longer procedure time.     

Endoscopic mucosal resection and endoscopic submucosal dissection for early gastric cancer: Current and original devices

Compared with endoscopic submucosal dissection (ESD), endoscopic mucosal resection (EMR) is easier to perform and requires less time for treatment. However, EMR has been replaced by ESD, because achieving en bloc resection of specimens > 20 mm in diameter is difficult with EMR. The technique of ESD was introduced to resect large specimens of early gastric cancer in a single piece. ESD can provide precise histological diagnosis and can also reduce the rate of recurrence, but has a high level of technical difficulty, and is consequently associated with a high rate of complications, a need for advanced endoscopic techniques, and a lengthy procedure time. To overcome disadvantages in both EMR and ESD, various advances have been made in submucosal injections, knives, other accessories, and in electrocoagulation systems.     

An evaluation of resectability among endoscopic treatment methods for rectal neuroendocrine tumors <10 mm

Background and Study AimsWith respect to rectal neuroendocrine tumor (NET) resection, it remains unclear which of the following methods is the most effective: conventional endoscopic mucosal resection (cEMR), EMR using a fitted cap (EMR-C), EMR with a ligation band device (EMR-L), or endoscopic submucosal dissection (ESD). Thus, in this study, we aim to retrospectively evaluate the most effective endoscopic resection for rectal NETs < 10 mm.Patients and methodsIn total, 61 consecutive patients with primary rectal NETs < 10 mm in diameter were included in this study; they were then divided into three groups: those with cEMR; those with modified EMR (mEMR) involving EMR-C and EMR-L; and those with ESD. The primary endpoint was to evaluate the difference in the complete en bloc resection rate. The secondary endpoint was to investigate differences in procedure time and complications.ResultsAmong the three groups, a significant difference was found in procedure time (cEMR vs ESD, P < .01; mEMR vs ESD, P < .01), en bloc resection rate (cEMR vs mEMR, P = .015), tumor size (mEMR vs ESD, P < .01), percentage of tumor diameter ≥ 5 mm (mEMR vs ESD, P < .01), and complete en bloc resection rate (cEMR vs mEMR, P = .014). Meanwhile, no significant difference was noted in terms of complication rate among the three groups.ConclusionThe mEMR was the most suitable resection method for rectal NETs < 10 mm with respect to the risks and benefits from procedure-related factors, such as complete en bloc resection rate, procedure time, and complication rate.     

Repeat endoscopic submucosal dissection for recurrent gastric cancers after endoscopic submucosal dissection

AIM: To clarify the safety and efficacy of repeat endoscopic submucosal dissection (re-ESD) for locally recurrent gastric cancers after ESD.METHODS: A retrospective evaluation was performed of the therapeutic efficacy, complications and follow-up results from ESD treatment for early gastric cancers in 521 consecutive patients with 616 lesions at St. Luke`s International Hospital between April 2004 and November 2012. In addition, tumor size, the size of resected specimens and the operation time were compared between re-ESD and initial ESD procedures. A flex knife was used as the primary surgical device and a hook knife was used in cases with severe fibrosis in the submucosal layer. Continuous variables were analyzed using the non-parametric Mann-Whitney U test and are expressed as medians (range). Categorical variables were analyzed using a Fisher’s exact test and are reported as proportions. Statistical significance was defined as a P-value less than 0.05.RESULTS: The number of cases in the re-ESD group and the initial ESD group were 5 and 611, respectively. The median time interval from the initial ESD to re-ESD was 14 (range, 4-44 mo). En bloc resection with free lateral and vertical margins was successfully performed in all re-ESD cases without any complications. No local or distant recurrence was observed during the median follow-up period of 48 (range, 11-56 mo). Tumor size was not significantly different between the re-ESD group and the initial ESD group (median 22 mm vs 11 mm, P = 0.09), although the size of resected specimens was significantly larger in the re-ESD group (median 47 mm vs 34 mm, P < 0.05). There was a non-significant increase observed in re-ESD operation time compared to initial ESD (median 202 min vs 67 min, respectively, P = 0.06).CONCLUSION: Despite the low patient number and short follow-up, the results suggest that re-ESD is a safe and effective endoscopic treatment for recurrent gastric cancer after ESD.     

Perspective on the practical indications of endoscopic submucosal dissection of gastrointestinal neoplasms

Endoscopic submucosal dissection （ESD） is a new endoluminal therapeutic technique involving the use of cutting devices to permit a larger resection of the tissue over the muscularis propria. The major advantages of the technique in comparison with polypectomy and endoscopic mucosal resection are controllable resection size and shape and en bloc resection of a large lesion or a lesion with ulcerative findings. This technique is applied for the endoscopic treatment of epithelial neoplasms in the gastrointestinal tract from the pharynx to the rectum. Furthermore, some carcinoids and submucosal tumors in the gastrointestinal tract are treated by ESD. To determine the indication, two aspects should be considered. The first is a little likelihood of lymph node metastasis and the second is the technical resectability. In this review, practical guidelines of ESD for the gastrointestinal neoplasms are discussed based on the evidence found in the literature.     

Current status of endoscopic submucosal dissection for the management of early gastric cancer: a Korean perspective

The early diagnosis of gastric cancer allows patients and physicians to pursue the option of endoscopic resection,which is significantly less invasive than conventional surgical resection.In Korea,the use of endoscopic submucosal dissection(ESD) has been increasing,and many reports on ESD have been published.In addition,Korean gastroenterologists from several hospitals performing ESD have conducted formal meetings to discuss useful information regarding ESD.Here,we discuss the Korean experience with ESD,inc...     

Treatment strategy for gastric non-invasive intraepithelial neoplasia diagnosed by endoscopic biopsy

Treatment strategies,whether as follow-up or"total incisional biopsy"for gastric noninvasive intraepithelial neoplasia diagnosed by examination of an endoscopic forceps biopsy specimen,are controversial due to problems associated with the diagnostic accuracy of endoscopic forceps biopsy and questions about the safety and efficacy of endoscopic treatment.Based on the histological findings of the biopsy specimen,it is difficult to differentiate between reactive or regenerative changes,inflammation and neoplastic changes,intraepithelial and invasive tumors.Therefore,gastric neoplasia diagnosed as noninvasive intraepithelial often develop into invasive carcinoma during follow-up.Recent advances in endoscopic modalities and treatment devices,such as image-enhanced endoscopy and highfrequency generators,may make endoscopic treatment,such as endoscopic submucosal dissection(ESD),a therapeutic option for gastric intraepithelial neoplasia,including low-grade neoplasms.Future studies are required to evaluate whether ESD is a valid strategy for gastric intraepithelial neoplasm with regard to safety and cost effectiveness.     

Outcome after endoscopic submucosal dissection for early gastric cancer in Korea

Endoscopic treatment,such as endoscopic mucosal resection(EMR) and endoscopic submucosal dissection(ESD),has been established as one of the treatment options for selected cases with early gastric cancer(EGC).Most studies on this topic have been carried out by researchers in Japan.Recently,the experience in EMR/ESD for EGC outside Japan is increasingly reported.In Korea,gastric cancer is the most common malignant disease,and the second leading cause of cancer death.Currently,EMR for EGC is widely performed i...     

阑尾腔内息肉内镜下治疗的初步观察

2016年1月—2020年12月间,在首都医科大学附属北京友谊医院消化内科行内镜下治疗的阑尾腔内息肉病例共6例,息肉直径0.3~1.3 cm。6例阑尾腔内息肉均顺利完成内镜下治疗,其中3例行内镜黏膜切除术整块切除、1例行内镜黏膜切除术分片切除、1例行内镜黏膜下剥离术切除、1例予活检钳冷钳除。6例术后均未出现出血、穿孔、感染和急性阑尾炎等并发症。3例术后复查创面愈合良好、无复发,其余3例暂未复查结肠镜。以上结果初步证实,阑尾腔内息肉行内镜下治疗安全和有效。     

内镜下黏膜切除术和内镜黏膜下剥离术治疗直肠类癌的对照研究

目的 评估内镜下黏膜切除术(EMR)和内镜黏膜下剥离术(ESD)治疗直肠类癌的有效性及安全性.方法 回顾性总结24例26处EMR治疗(EMR组)和19例20处ESD治疗(ESD组)的直肠类癌患者的临床资料,对比分析两组在病灶大小、手术时间、病灶整块切除率、组织病理学治愈性切除率、并发症及随访结果方面的差异.结果 ESD组术前超声内镜测量的直径大小为(7.4 ±5.3)mm,明显大于EMR组的(5.6 ±2.1)mm(P ＜0.05);ESD组手术时间为(32.6±10.5)min,明显长于EMR组的(8.9±6.3)min(P ＜0.05);EMR组和ESD组病灶均一次性完整切除,整块切除率均为100.0％;EMR组的组织病理学治愈性切除率为100.0％(26/26),略高于ESD组的95.0％ (19/20) (P＞0.05);EMR术后出血、穿孔并发症发生率为15.3％ (4/26),明显高于ESD组的5.0％ (1/20) (P＜0.05);两组在术后复查随访,均未发现局部复发.结论 对于直径小于7 mm的病灶应用EMR方法可以有效完整地切除病灶,并缩短手术时间;而对于直径大于7 mm和经过多次活检或局部切除后内镜下注射抬举征阴性的病灶,采取ESD的手术方式,方能得到比较满意的治疗效果.     

Propofol sedation during endoscopic treatment for early gastric cancer compared to midazolam

Endoscopic submucosal dissection (ESD) has been proposed as the gold standard in the treatment of early gastric cancer because it facilitates a more accurate histological assessment and reduces the risk of tumor recurrence. However, the time course of ESD for large gastric tumors is frequently prolonged because of the tumor size and technical difficulties and typically requires higher doses of sedative and pain-controlling drugs. Sedative or anesthetic drugs such as midazolam or propofol are used during the procedure. Therapeutic endoscopy of early gastric cancers can often be performed with only moderate sedation. Compared with midazolam, propofol has a very fast onset of action, short plasma half-life and time to achieve sedation, faster time to recovery and discharge, and results in higher patient satisfaction. For overall success, maintaining safety and stability not only during the procedure but also subsequently in the recovery room and ward is necessary. In obese patients, it is recommended that the injected dose be based on a calculated standard weight. Cooperation between gastroenterologists, surgeons, and anesthesiologists is imperative for a successful ESD procedure.     

单中心早期胃癌内镜下治疗10年回顾性研究

目的：探讨早期胃癌内镜下治疗的疗效、安全性及其影响因素。 方法：回顾性分析2006年1月至2015年12月于北京协和医院消化内镜中心拟诊早期胃癌、接受内镜下治疗并证实的病例186例次,根据内镜下治疗适应证分组,统计治愈性切除率及并发症的发生率,分析其影响因素。统计随访事件的发生情况。 结果：研究期间,接受内镜下切除的早期胃癌共186例次,绝对适应证组治愈性切除率86.9%（73/84）,扩大适应证组61.7%（50/81）,非适应证组33.3%（7/21）,不同适应证组治愈性切除率有显著差异（P<0.01）。多因素分析显示,胃下1/3、无溃疡、直径≤2cm、无黏连、分化型癌均为治愈性切除的独立预测因素。病理分化程度改变或浸润深度升级是完全切除的扩大适应证病变无法达到治愈性切除的主要原因。出血及穿孔的发生率分别为4.8%（9/186）、3.8%（7/186）。胃下1/3、无黏连、整块切除的病变穿孔发生率低,差异有统计学意义。成功随访154例患者,中位随访时间22.3个月。治愈性切除者同时癌及异时癌的发生率分别为7.5%、0.9%。 结论：早期胃癌内镜下治疗的绝对适应证患者其治愈性切除率高;而扩大适应证者采取内镜下治疗需慎重。术前应进行细致的内镜评估,尤其是辨别未分化成分及垂直浸润深度。内镜治疗后应密切随访以早期发现同时癌及异时癌     

Endoscopic submucosal dissection for colorectal neoplasms

Although endoscopic submucosal dissection (ESD) gains acceptance as one of the standard treatments for esophageal and stomach neoplasms in Japan, it is still in the developing stage for colorectal neoplasms. In terms of indications, little likelihood of nodal metastasis and technical resectability are principally considered. Some of intramucosal neoplasms, carcinomas with minute submucosal invasion, and carcinoid tumors, which are technically unresectable by conventional endoscopic treatments, may become good candidates for ESD, considering substantial risks and obtained benefits. ESD as a staging measure to obtain histological information of the invasion depth and lymphovascular infiltration is acceptable because preoperative prediction is difficult in some cases. In terms of techniques, advantages of ESD in comparison with other endoscopic treatments are to be controllable in size and shape, and to be resectable even in large and fibrotic neoplasms. The disadvantages may be longer procedure time, heavier bleeding, and higher possibility of perforation. However, owing to refinement of the techniques, invention of devices, and the learning curve, acceptable technical safety has been achieved. Colorectal ESD is very promising and become one of the standard treatments for colorectal neoplasms in the near future.     

内镜黏膜下剥离术和内镜下黏膜切除术治疗早期胃癌的术后出血影响因素分析

目的：分析影响早期胃癌内镜黏膜下剥离术和内镜下黏膜切除术(ESD/EMR)术后出血的可能影响因素,以便降低出血风险,对术后出血高危人群进行特殊关注。方法：回顾性收集2012年6月至2018年5月于北京友谊医院内镜中心因诊断早期胃癌而行ESD/EMR治疗患者的临床资料,包括病人基本信息(年龄、性别、疾病史)、临床特征(病变大小、部位、形态)及术后病理信息(病理类型、浸润深度)等,分析上述因素对ESD/EMR术后发生出血的影响。结果：共有255例早期胃癌患者纳入研究,其中11例发生术后出血(4.3%)。术后出血病例与未出血病例相比,心脑血管疾病史、氯吡格雷服药史、多发病变在两组间分布有统计学差异 (P=0.004, P=0.017及P=0.042)。多因素分析显示心脑血管疾病史(OR=5.151, 95% CI：1.242-21.356, P=0.024)、多发病变(OR=7.245, 95% CI：1.471-35.684, P=0.015)及主要病变≥2cm (OR=4.713, 95%CI：1.011-21.982, P=0.048)是术后发生出血的可能危险因素。生存分析结果显示：有心脑血管疾病史(P<0.001)、多发病变(P=0.013)、主要病变≥2cm的患者(P=0.031),ESD/EMR术后发生出血的风险明显增高。结论：ESD/EMR术后应重点关注具有心脑血管疾病史、病变部位多发、病变较大的患者的出血风险。     

Benefits of endoscopic submucosal dissection according to size and location of gastric neoplasm, compared with conventional mucosal resection

Background and Aims:  To clarify optimal therapeutic strategies for early gastric cancers without vestigial remnant or recurrence, we evaluated the benefits of endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) according to tumor size and location.
Methods:  From January 2000 to December 2007, a total of 328 gastric lesions were treated using conventional EMR, while 572 lesions were treated by ESD. Patients who underwent surgery on the upper gastrointestinal tract before EMR or ESD were excluded from the study. We compared tumor size, location and rates of complete resection, curative resection, postoperative bleeding, perforation and local recurrence between EMR and ESD according to tumor situation.
Results:  Overall local complete resection rate (EMR, 64.2%; ESD, 95.1%) and overall curative resection rate (EMR, 59.5%; ESD, 82.7%) were significantly higher in ESD than in EMR. No significant differences were seen in complication rates between EMR and ESD. Local recurrence was detected in 13 lesions (4.0%) of the EMR group during follow up. In contrast, no local recurrence was detected in the ESD group. For lesions 5 mm or less in diameter, complete resection rate in the EMR group was not significantly inferior to that in the ESD group at any location. However, rates were overwhelmingly better in the ESD group than in the EMR group for lesions more than 5 mm in diameter, regardless of location.
Conclusion:  We concluded that lesions exceeding 5 mm in diameter should be treated by ESD, although a high resection rate is obtained also with EMR for lesions of 5 mm or less in diameter.     

Spectrum of final pathological diagnosis of gastric adenoma after endoscopic resection

AIM: To investigate how many discrepancies occur in patients before and after endoscopic treatment of referred adenoma and the reason for these results. METHODS: We retrospectively reviewed data from 554 cases of 534 patients who were referred from primary care centres for adenoma treatment and treated for endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) at Chungnam National University Hospital, from July 2006 to June 2009. Reendoscopy was examined in 142 cases and biopsywas perf...     

内镜黏膜下剥离术与外科手术治疗残胃异时性早期癌的临床效益对比

目的　回顾性对比残胃异时性早期癌（metachronous early gastric cancer,MEGC）的组织病理特征及不同治疗方式的疗效。方法　收集2014年1月至2020年12月鼓楼医院的残胃MEGC患者资料66例,按治疗方案分为内镜黏膜下剥离术（endoscopic submucosal dissection,ESD）组38例和外科手术组28例,分析比较2组的基线特征、病理特征、治疗效果及费用差异。结果　66例残胃MEGC患者年龄（69.7±8.5）岁,多为男性,残胃时间平均6年。肿瘤位置,ESD组以胃体（31.6%）为主,外科手术组以贲门为主（53.6%）,差异存在统计学意义（χ2=11.070,P=0.028）。平均手术时间、住院时间、术后禁食时间以及合计医疗费,ESD组分别为80.0 min、6.0 d、1.5 d、19 436元,外科手术组分别为215.0 min、19.0 d、6.5 d、68 665元,组间差异均有统计学意义（P<0.05）。随访期间生存率,ESD组76.3%,外科手术组71.4%,组间差异无统计学意义（χ2=0.736,P=0.778）。并发症方面,ESD组出血7.9%、感染5.3%,外科手术组梗阻、感染均为14.3%,术后梗阻在组间差异有统计学意义（P<0.05）。结论　ESD治疗残胃异时性癌安全有效,且在治疗费用和时间消耗方面优于外科手术,但其长期疗效仍需大样本前瞻性临床研究结果验证。